Investment Analysts’ Weekly Ratings Changes for Phreesia (PHR)

Phreesia (NYSE: PHR) recently received a number of ratings updates from brokerages and research firms:

• 5/30/2026 – Phreesia was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/29/2026 – Phreesia had its “market perform” rating reaffirmed by Citigroup Inc..
• 5/28/2026 – Phreesia had its price target raised by Truist Financial Corporation from $11.00 to $12.00. They now have a “hold” rating on the stock.
• 5/28/2026 – Phreesia had its price target lowered by Canaccord Genuity Group Inc. from $22.00 to $16.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Phreesia had its price target raised by Citigroup Inc. from $10.00 to $12.00. They now have a “neutral” rating on the stock.
• 5/28/2026 – Phreesia was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $12.00 price target on the stock.
• 5/28/2026 – Phreesia had its “buy” rating reaffirmed by DA Davidson. They now have a $14.00 price target on the stock.
• 5/20/2026 – Phreesia had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $9.00 price target on the stock, down from $15.00.
• 5/20/2026 – Phreesia was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $9.00 price target on the stock, down from $15.00.
• 5/14/2026 – Phreesia had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $10.00 price target on the stock, down from $24.00.
• 5/14/2026 – Phreesia was downgraded by Barclays PLC from “overweight” to “equal weight”. They now have a $10.00 price target on the stock, down from $24.00.

Insider Buying and Selling

In other Phreesia news, insider David Linetsky sold 8,332 shares of the company’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $8.07, for a total value of $67,239.24. Following the completion of the sale, the insider owned 224,056 shares in the company, valued at $1,808,131.92. This represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Yvonne Hui sold 10,063 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $9.08, for a total value of $91,372.04. Following the completion of the sale, the insider owned 25,991 shares of the company’s stock, valued at approximately $235,998.28. The trade was a 27.91% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 50,493 shares of company stock worth $461,983. Corporate insiders own 5.20% of the company’s stock.

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.